Clinical trial · Observational

FLNA in HCC Patients

Filamin A Expression in HCC Patients

NCT03081637CI-TRIAL-00027938completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The risk of recurrence after hepatectomy for hepatocellular carcinoma (HCC) is very high. Having a predictive marker of early recurrence (ER) would be desirable to personalize the follow-up and possibly develop new targeted therapy. The aim of this study was to test the expression of Filamin A (FLNA) in a cohort of patients operated for HCC.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Hepatocellular Carcinoma	Hepatocellular Carcinoma	ONTOLOGY_EXACT	0.98

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Rate of expression of Filamin A (FLNA) in HCC specimens from patients resected for HCC.
timeFrame
2 years after surgery as a minimum follow-up
description
The rate of expression of FLNA in HCC specimens will be measured using standard immunohistochemistry methodology on surgical specimens. Such expression rate will be correlated to several different clinical and pathological parameters.

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

* The inclusion criteria were represented by the histological positivity for HCC with complete clinical, surgical, pathological, and follow-up data.

Exclusion Criteria:

* Patients preoperatively treated with chemotherapy or trans-arterial therapy were excluded.
* Similarly, patients operated for recurrent HCC or with non-radical surgery or with missing data were excluded.

References

Publications (0)

Data not yet available

No reference posted for this study.